Latest News for: q32

Edit

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

The Facts 18 Feb 2026
18, 2026 /PRNewswire/ -- Q32 Bio Inc ... QTTB) ("Q32 Bio"), a ...
Edit

Q32 Bio Announces $10.5 Million Registered Direct Offering

Citizen Tribune 17 Feb 2026
17, 2026 /PRNewswire/ -- Q32 Bio Inc ... QTTB) ("Q32 Bio"), a ...
Edit

Q32 Bio Announces $10.5 Million Registered Direct Offering (Form 8-K) (Q32 Bio Inc)

Public Technologies 17 Feb 2026
Q32 Bio Announces $10.5 Million Registered Direct Offering ... 17, 2026 /PRNewswire/ - Q32 Bio Inc ... The gross proceeds to Q32 Bio from this offering are expected to be approximately $10.5 million, before deducting certain offering expenses ... About Q32 Bio.
Edit

Supplemental Prospectus (Form 424B5) (Q32 Bio Inc)

Public Technologies 17 Feb 2026
and referred to herein as Legacy Q32), with Legacy Q32 continuing as the surviving entity as a wholly-owned subsidiary of Homology (the "Merger") ... and referred to herein as Legacy Q32), with ...
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Q32 Bio Inc)

Public Technologies 31 Jan 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... OMB Number. 3235-0287 ... 2 ... Q32 Bio Inc ... Q32 BIO INC., 830 WINTER STREET 3 ... Q32 BIO INC ... Q32 Bio Inc.
Edit

Notice of Proposed Sale of Securities (Form 144) (Q32 Bio Inc)

Public Technologies 02 Dec 2025
). The text version of this document is not available ... Q32 Bio Inc.
Edit

Q32 Bio Sells Complement Inhibitor ADX-097

The Galveston Daily News 01 Dec 2025
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- ....
Edit

Q32 Bio Sells Complement Inhibitor ADX-097 (Form 8-K) (Q32 Bio Inc)

Public Technologies 01 Dec 2025
Q32 Bio Sells Complement Inhibitor ADX-097 ... -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs --.
  • 1

Article Search

tools
×
×
×
×